Media Doctor Canada
Follow us on Twitter








"Drug limits damage in early MS: study"


Source: CBC.CA

Published: 23 Oct 2021

Category: Pharmaceutical

Rating: (4 stars)

what they said (Hover the mouse cursor over underlined words for more info)

A drug licensed to treat a type of leukemia appears to reduce the damaging effects of multiple sclerosis in its early stages, researchers said Thursday.

In a three-year study published in the New England Journal of Medicine, alemtuzumab reduced clinical relapses and the development of new disability compared with those who received a current treatment...

The original article can be found at:

how did it rate? (more information)

Criteria Rating
Total Score 7 of 9
Availability of Treatment Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Satisfactory (?)
Costs of Treatment Not Applicable
Evidence Not Satisfactory (?)
Quantification of Benefits of Treatment Satisfactory (?)
Harms of Treatment Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

As a general statement, this story about alemtuzumab (a drug in the relatively early stages of research) is more complete than most stories that we review. The information provided in this story gives a detailed picture about the safety and efficacy of the product, allowing readers to make an informed decision about this new product. It also points out that the efficacy of alemtuzumab has only been compared to some of the currently available treatment options for MS. The story mentions that the drug was evaluated in a clinical trial but doesn't state whether or not it was a randomized control trial. The inclusion of further details about the study design and potential conflicts of interest are the only aspects that might be expanded upon and provided to the readers.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada